Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Anthony Paul Gulati"'
Autor:
Markus D. Siegelin, Angela Lignelli, Helen Remotti, Jeffrey N. Bruce, Robert L. Fine, Arthur S. Carminucci, Sharon L. Wardlaw, Anthony Paul Gulati, Brad E. Zacharia
Publikováno v:
Neurosurgery. 74:E447-E455
Background and importance Rarely, corticotrophic pituitary tumors take on an aggressive form characterized by rapid growth, invasion into local structures, compression of cranial nerves, and possible spread to distant sites. When conventional surgery
Autor:
Rebecca A. Moss, John D. Allendorf, John A. Chabot, Beth Schrope, James A. Lee, Peter D. Stevens, Yuehua Mao, Stephen M. Schreibman, Dawn Tsushima, William H. Sherman, Benjamin A. Krantz, Kelley B. Mowatt, Anthony Paul Gulati, Richard D. Dinnen, Robert L. Fine
Publikováno v:
Cancer Chemotherapy and Pharmacology. 71:663-670
We evaluated the efficacy and safety of capecitabine and temozolomide (CAPTEM) in patients with metastatic neuroendocrine tumors (NETs) to the liver. This regimen was based on our studies with carcinoid cell lines that showed synergistic cytotoxicity
Autor:
Robert L. Fine, Stephen M. Schreibman, Anthony Paul Gulati, Benjamin A. Krantz, Kelley B. Mowatt, Wendy N Moyal, Rebecca A. Moss, Dawn Tsushima
Publikováno v:
Oncology. 84:127-134
Background: Neuroendocrine tumors are uncommon tumors that are histopathologically and biologically heterogeneous and include the multiple endocrine neoplasia (MEN) 1 and 2 syndromes. The morbidity of MEN-1 and MEN-2 is often due to the symptomatolog
Autor:
Robert L. Fine, Anthony Paul Gulati
Brain metastases are a serious consequence of solid tumors that often result in significant morbidity and mortality, with the highest incidence rates in lung cancers and melanoma. In this chapter, we will review the highly specialized structure of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d7e14d265ff66003638753d46be5b33
https://doi.org/10.1016/b978-0-12-803508-5.00002-0
https://doi.org/10.1016/b978-0-12-803508-5.00002-0
Autor:
Érica S.S. Araújo, Mohammad Bashashati, Shivani Bassi, Giuseppe Cirino, Frances A. Collichio, Michael A. Davies, Renata Duchnowska, Alexander Engelman, Majid Esmaeilzadeh, Matthew G. Ewend, Robert Lance Fine, Caterina Fontanella, Peter A. Forsyth, Gurpreet S. Gandhoke, Isabella C. Glitza, Anthony Paul Gulati, Jun Guo, M.A. Hayat, Amy Heimberger, Eirik Helseth, Angela M. Hong, Angela Ianaro, Jacek Jassem, Juraj Kavecansky, Damien Kee, Mohammad Reza Keramati, Michael N. Khoury, Ana C.V. Krepischi, Young Kwok, Peter Lau, Supriya Lal, Estelle Leclerc, Carrie B. Lee, Georgina V. Long, L. Dade Lunsford, Megan Lyle, Lili Mao, Torstein R. Meling, Symeon Missios, Edward A. Monaco, Stergios J. Moschos, Elizabeth Nichols, Ajay Niranjan, Etin-Osa Osa, Anna C. Pavlick, Dimitrius T. Pramio, Fabio Puglisi, Siril G. Rogne, Brindha Shivalingam, Erik P. Sulman, Konstantina Svokos, Toshihide Tanaka, Ahmad A. Tarhini, John F. Thompson, Steven A. Toms, Nam D. Tran, Dimitri Trembath, Sarah A. Weiss, Timothy M. Zagar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49729cc0971fffcf73601f2e66141ee1
https://doi.org/10.1016/b978-0-12-803508-5.00026-3
https://doi.org/10.1016/b978-0-12-803508-5.00026-3
Publikováno v:
JOP : Journal of the pancreas. 13(3)
Publikováno v:
Anticancer research. 32(4)
Gastrointestinal stromal tumor (GIST) is a mesenchymal malignancy of the gastrointestinal tract. Imatinib mesylate (Gleevec(®), ST1571, Novartis Pharmaceuticals, Basel, Switzerland) is a selective inhibitor of break point cluster-Ableson (BCR-ABL),
Autor:
Kelley B. Mowatt, James A. Lee, Anna Oprescu, Yoomi Lee, William H. Sherman, Ronald D. Ennis, John A. Chabot, Stephen M. Schreibman, Kyung Chu, Robert L. Fine, Beth Schrope, Anthony Paul Gulati, Dawn Tsushima, John D. Allendorf
Publikováno v:
Journal of Clinical Oncology. 32:274-274
274 Background: Chemoradiation (CRT) is used in unresectable pancreatic cancer (PC) to convert patients to a resectable state. Those who go to surgery can have a similar survival as those initially deemed resectable, with a mOS of 8.2-9 mo. We recent
Autor:
Anna Oprescu, John A. Chabot, Jeffrey N. Bruce, Robert L. Fine, Anthony Paul Gulati, Kelley B. Mowatt, Dawn Tsushima
Publikováno v:
Journal of Clinical Oncology. 32:179-179
179 Background: We found in our lab that capecitabine (CAP), the prodrug of 5-FU, and temozolomide (TEM) were synergistic in inducing apoptosis in BON neuroendocrine tumor (NET) cell lines. We were the first to report in 2004 the use and mechanism of
Autor:
Stephen M. Schreibman, Paul E. Oberstein, John A. Chabot, John D. Allendorf, Beth Schrope, William H. Sherman, James A. Lee, Kelley B. Mowatt, Yoomi Lee, Anthony Paul Gulati, Kyung Chu, Robert L. Fine, Dawn Tsushima
Publikováno v:
Journal of Clinical Oncology. 31:209-209
209 Background: We found that in pancreatic cancer (PC) cells, when gemcitabine, docetaxel, capecitabine (GTX) are given in a sequence and time specific manner, it 1) increased Bax, Bak, Fas and decreased Bcl-2 and Bcl-XL expression; 2) increased hEN